Illumigen Biosciences of Seattle, a spinoff company from the University of Washington Genome Center, was recently acquired by Cubist Pharmaceuticals of Lexington, Mass. Illumigen’s prospective drug to treat Hepatitis C virus was the basis of the acquisition. Illumigen was formed in 2000 by faculty/staff from the Genome Center (housed in the Washington Technology Center facility).
Related external links (will open a new window):
– end of post –